ABOUT DALCOR

DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene (ADCY9 AA genotype).

Dalcetrapib is currently being evaluated in the Dal-GenE-2 (DAL-302) Phase 3 cardiovascular clinical outcomes confirmatory trial aiming to reduce fatal and non-fatal myocardial infarction (MI) in 2000 patients with post-acute coronary syndrome (ACS) who have the ADCY9 AA genotype. This confirmatory trial follows the results of the dal-GenE trial which showed a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and a 45% RRR in 1,200 patients in North America.

To date, dalcetrapib has been administered, with a good safety and tolerability profile, to over 15,000 patients with cardiovascular diseases and risk factors such as obesity, diabetes, and hypertension.

The frequency of the ADCY9 AA genotype is up to 20% in the total population and is higher than 40% in populations with African ancestry.

DalCor Pharmaceuticals holds the worldwide exclusive license to develop, manufacture and commercialise dalcetrapib, and holds the right to the genetic marker for use with dalcetrapib in patients with the ADCY9 AA genotype. A companion diagnostic test, developed in conjunction with Roche Molecular Systems, identifies patients with the ADCY9 AA genotype who may potentially benefit from dalcetrapib treatment.